Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. Issue 1 (21st September 2015)

• Record Type: Journal Article
• Authors: Saigusa, Takamitsu; Dang, Yujing; Mullick, Adam E.; Yeh, Steve T.; Zile, Michael R.; Baicu, Catalin F.; Bell, P. Darwin
• Is Part Of: FASEB journal. Volume 30:Issue 1(2016)
• Page Start: 370
• Page End: 379
• Publication Date: 2015-09-21
• Subjects: renin angiotensin system -- antisense oligonucleotide -- polycystic kidney disease -- hypertension; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.15-279299
• Languages: English
• ISSNs: 0892-6638

Abstract

ABSTRACT: Activation of the intrarenal renin angiotensin system (RAS) is believed to play an important role in the development of hypertension and cystogenesis in autosomal dominant polycystic kidney disease (ADPKD). Results of clinical studies testing RAS inhibitors in slowing the progression of cystic disease in ADPKD are inconclusive, and we hypothesized that current RAS inhibitors do not adequately suppress intrarenal RAS. For this study, we compared a novel Gen 2 antisense oligonucleotide (ASO) that inhibits angiotensinogen (Agt) synthesis to lisinopril in adult conditional Pkd1 systemic‐knockout mice, a model of ADPKD. Six weeks after Pkd1 global gene knockout, the mice were treated with Agt‐ASO (66 mg/kg/wk), lisinopril (100 mg/kg/d), PBS (control), or scrambled ASO (66 mg/kg/wk) for 10 wk, followed by tissue collection. Agt ASO resulted in significant reduction in plasma, liver, and kidney Agt, and increased kidney renin compared with control treatments. Kidneys from Agt‐ASO‐treated mice were not as enlarged and showed reduced cystic volume compared with lisinopril or control treatments. Blood pressure was better controlled with lisinopril than with Agt‐ASO. Agt‐ASO suppressed cell proliferation in both cystic and noncystic cells compared with lisinopril and control treatments. However, Agt‐ASO did not reduce cell proliferation in liver, which indicates that Agt‐ASO targets cell signaling pathways that specifically suppresses cystogenesis in the kidney. These data suggest that Agt‐ASO effectively attenuates intrarenal RAS and therefore can be a novel and effective agent for treating ADPKD.—Saigusa, T., Dang, Y., Mullick, A.E., Yeh, S.T., Zile, M.R., Baicu, C. F., Bell, P. D. Suppressing angiotensinogen synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J. 30, 370‐379 (2016). www.fasebj.org